Business Context and Reporting Period
This Form 8-K reports on the results of a special meeting of stockholders for NanoVibronix, Inc. (trading symbol: NOAV), reconvened on May 6, 2021, following adjournments in March and April. The filing addresses corporate governance matters regarding authorized share capital. Note: The request metadata references "Envue Medical, Inc.," but the filing text explicitly identifies the registrant as NanoVibronix, Inc.
Key Financial Metrics
This filing is a current report regarding stockholder voting results and does not contain financial performance data. There is no information provided regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Three proposals were submitted to stockholders. The voting outcomes were as follows:
- Proposal 1 (Approved): Ratification of a prior increase in authorized Common Stock from 20,000,000 to 24,109,635 shares (effective December 4, 2020) and ratification of issuances upon conversion/exercise.
- Capital Stock Votes For: 13,289,420
- Capital Stock Votes Against: 1,201,004
- Proposal 2 (Not Approved): Amendment to increase authorized Common Stock from 20,000,000 (or 24,109,635 if Proposal 1 passed) to 45,000,000 shares.
- Capital Stock Votes For: 12,780,650
- Capital Stock Votes Against: 1,474,468
- Proposal 3 (Approved): Approval to adjourn the meeting if necessary to solicit additional proxies for Proposals 1 and 2.
- Votes For: 13,244,283
- Votes Against: 1,160,907
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are detailed in this document beyond the standard disclosure of the voting process.
Investor Verification Checklist
- Verify the discrepancy between the request metadata ("Envue Medical, Inc.") and the filing registrant ("NanoVibronix, Inc.").
- Confirm the impact of the failed Proposal 2 on the company's ability to issue new shares for future financing or acquisitions.
- Review the definitive proxy statement filed on March 3, 2021, for detailed rationale behind the capital structure proposals.
- Check subsequent filings to determine if the company attempted to re-propose the 45,000,000 share authorization increase.